GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lexicon Pharmaceuticals Inc (STU:LX31) » Definitions » Debt-to-Asset

Lexicon Pharmaceuticals (STU:LX31) Debt-to-Asset : 0.26 (As of Mar. 2024)


View and export this data going back to . Start your Free Trial

What is Lexicon Pharmaceuticals Debt-to-Asset?

Lexicon Pharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was €1.19 Mil. Lexicon Pharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was €96.56 Mil. Lexicon Pharmaceuticals's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Mar. 2024 was €383.84 Mil. Lexicon Pharmaceuticals's debt to asset for the quarter that ended in Mar. 2024 was 0.25.


Lexicon Pharmaceuticals Debt-to-Asset Historical Data

The historical data trend for Lexicon Pharmaceuticals's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lexicon Pharmaceuticals Debt-to-Asset Chart

Lexicon Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.59 0.06 0.02 0.29 0.46

Lexicon Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.34 0.33 0.38 0.46 0.26

Competitive Comparison of Lexicon Pharmaceuticals's Debt-to-Asset

For the Biotechnology subindustry, Lexicon Pharmaceuticals's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lexicon Pharmaceuticals's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lexicon Pharmaceuticals's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Lexicon Pharmaceuticals's Debt-to-Asset falls into.



Lexicon Pharmaceuticals Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Lexicon Pharmaceuticals's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(1.184 + 96.077) / 210.386
=0.46

Lexicon Pharmaceuticals's Debt-to-Asset for the quarter that ended in Mar. 2024 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(1.188 + 96.557) / 383.841
=0.25

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Lexicon Pharmaceuticals  (STU:LX31) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.


Lexicon Pharmaceuticals Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Lexicon Pharmaceuticals's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Lexicon Pharmaceuticals (STU:LX31) Business Description

Traded in Other Exchanges
Address
2445 Technology Forest Boulevard, 11th Floor, The Woodlands, TX, USA, 77381
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drugs candidates are LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain; and sotagliflozin, an orally-delivered small molecule drug candidate, as a treatment for heart failure and type 1 diabetes.

Lexicon Pharmaceuticals (STU:LX31) Headlines

No Headlines